

Special Issue

The Genetic Basis of High-Altitude Pulmonary Hypertension

Message from the Guest Editor

Pulmonary arterial hypertension (PAH) is a rare disease characterized by an abnormal increase in the mean pressure of the pulmonary artery (≥ 25 mm Hg at rest), leading to a progressive increase in pulmonary vascular resistance and, ultimately, at death due to right ventricular failure. More than 80% of inheritable PAH cases are caused by mutations in the *BMPR2* gene. In contrast, high altitude pulmonary hypertension (HAPH) only develops acutely at high altitude, affecting individuals residing at altitudes equal to or greater than 2,500 meters. Numerous pathogenic variables may be involved in the development of the disease, but since HAPH affects only some people who live at high altitudes, genetic factors may play an important role in its pathogenesis. Unlike HAP, mutations have not yet been identified in individuals with HAPH, although recent studies have identified potential protective genetic variants in non-HAPH subjects. Besides genetic variants, other mechanisms could also play a role in HAPH susceptibility.

This Special Issue will focus on current knowledge and the latest developments regarding the genetic underpinnings of high altitude pulmonary hypertension.

Guest Editor

Dr. Irene Madrigal

Biochemistry and Molecular Genetics Department, Hospital Clínic of Barcelona, 08028 Barcelona, Spain

Deadline for manuscript submissions

closed (28 February 2021)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/50854

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))